Vivos Therapeutics Inc is a medical technology company focused on developing and commercializing innovative solutions for the treatment of obstructive sleep apnea and other sleep-related disorders. The company specializes in non-invasive therapies, including uniquely designed oral appliances that aim to improve airway patency during sleep. Vivos Therapeutics collaborates with dental practitioners and healthcare professionals to provide comprehensive care options for patients, enhancing both their sleep quality and overall health. Through its research and development efforts, the company seeks to advance the understanding of sleep disorders and create effective therapies that address the underlying causes of these conditions.
The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive sleep apnea and snoring in children aged 6-17.
Vivos Therapeutics shares are trading lower Tuesday. The company filed a prospectus related to the resale of up to 1.73 million shares of common stock by selling shareholders. Vivos said that if the warrants held by the selling stockholder are exercised in full for cash, the company would receive approximately $8.4 million.
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading
